Liu Zhili, Sun Yuzhe, Zhen Hefu, Nie Chao
College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
BGI-Shenzhen, Shenzhen 518083, China.
Evid Based Complement Alternat Med. 2022 Mar 27;2022:1340194. doi: 10.1155/2022/1340194. eCollection 2022.
Hepatocellular carcinoma (HCC) is the fourth main reason of cancer-related death. is a commonly used traditional Chinese medicine (TCM) for patients with HCC. However, its potential mechanism for treatment of HCC remains unclear. Here, we used transcriptomics and network pharmacology to explore the potential molecular mechanisms of . In our study, twelve differentially expressed genes (DEGs) (5 upregulated and 7 downregulated) of treating HepG2 cells (a kind of HCC cell) were identified. Among the 12 DEGs, HMOX1 may play an essential role. mainly affects the mineral absorption pathway in HCC. We acquired 2957, 1877, and 255 targets from TCMID, SymMap, and TCMSP, respectively. could upregulate HMOX1 via luteolin, capsaicin, and sulforaphane. Our study provided new understanding of the potential pharmacological mechanisms of in treating HCC and pointed out a direction for further experimental research.
肝细胞癌（HCC）是癌症相关死亡的第四大主要原因。[具体药物名称未给出]是一种常用于HCC患者的传统中药。然而，其治疗HCC的潜在机制仍不清楚。在此，我们使用转录组学和网络药理学来探索[具体药物名称未给出]的潜在分子机制。在我们的研究中，鉴定出了[具体药物名称未给出]处理HepG2细胞（一种HCC细胞）的12个差异表达基因（DEG）（5个上调和7个下调）。在这12个DEG中，HMOX1可能起关键作用。[具体药物名称未给出]主要影响HCC中的矿物质吸收途径。我们分别从中药综合数据库（TCMID）、SymMap和中药系统药理学数据库（TCMSP）中获取了2957个、1877个和255个靶点。[具体药物名称未给出]可通过木犀草素、辣椒素和萝卜硫素上调HMOX1。我们的研究为[具体药物名称未给出]治疗HCC的潜在药理机制提供了新的认识，并为进一步的实验研究指明了方向。
